

---

**THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION**

---

**If you are in any doubt** as to any aspect of this circular or as to the action to be taken, you should consult your licensed securities dealer or other registered institution in securities, bank manager, solicitor, certified public accountant or other professional adviser.

**If you have sold or transferred** all your shares in **LifeTech Scientific Corporation** (先健科技公司), you should at once hand this circular and the accompanying form of proxy to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

---



**LIFETECH SCIENTIFIC CORPORATION**

**先健科技公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1302)**

**(1) GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES**  
**(2) RE-ELECTION OF DIRECTORS AND CONTINUOUS APPOINTMENT OF**  
**INDEPENDENT NON-EXECUTIVE DIRECTOR**  
**(3) RE-APPOINTMENT OF AUDITORS**  
**AND**  
**(4) NOTICE OF ANNUAL GENERAL MEETING**

---

A notice convening the annual general meeting of LifeTech Scientific Corporation (先健科技公司) (the “**Company**”) to be held at Floor 16, LifeTech Scientific Building, No. 22, Keji 12th Road South, High-tech Park, Nanshan District, Shenzhen, PRC on Thursday, 28 May 2026 at 10:00 a.m. is set out on pages 21 to 25 of this circular.

A form of proxy for use at the annual general meeting is enclosed. Whether or not you are able to attend the annual general meeting in person, you are advised to complete the enclosed form of proxy in accordance with the instructions printed thereon as soon as possible and return the completed form of proxy to the Company’s branch share registrar in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for holding such annual general meeting or any adjournment thereof. Completion and return of the form of proxy will not preclude you from attending and voting in person at the annual general meeting or any adjourned meeting if you so wish and in such event, the form of proxy shall be deemed to be revoked.

6 May 2026

---

## CONTENTS

---

	<i>Page</i>
<b>Definitions</b> .....	1
<b>Letter from the Board</b> .....	3
<b>Appendix I Explanatory Statement</b> .....	9
<b>Appendix II Details of the Directors Proposed to be Re-elected at the Annual General Meeting</b> .....	12
<b>Notice of Annual General Meeting</b> .....	21

---

## DEFINITIONS

---

*In this circular, the following words and expressions shall have the following meanings unless the context requires otherwise:*

“AGM”	the annual general meeting of the Company to be convened and held at Floor 16, LifeTech Scientific Building, No. 22, Keji 12th Road South, High-tech Park, Nanshan District, Shenzhen, PRC on Thursday, 28 May 2026 at 10:00 a.m. or where the context so admits, any adjournment thereof
“Articles of Association”	the memorandum and articles of association of the Company, as amended from time to time
“Board”	the board of Directors
“Directors”	the directors of the Company
“Companies Act”	the Companies Act, Cap 22 (Law 3 of 1961, as consolidated and revised from time to time) of the Cayman Islands
“Company”	LifeTech Scientific Corporation (先健科技公司), a company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the main board of the Stock Exchange
“General Mandates”	the Issue Mandate and Repurchase Mandate
“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Issue Mandate”	the general and unconditional mandate proposed to be granted to the Directors at the AGM to exercise the power of the Company to allot, issue or otherwise deal with additional Shares and to sell or transfer treasury shares of the Company (if any) of up to 20% of the issued share capital of the Company (excluding treasury shares of the Company, if any) as at the date of passing of the relevant resolution granting such mandate
“Latest Practicable Date”	30 April 2026, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained herein
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“Nomination Committee”	the nomination committee of the Board

---

## DEFINITIONS

---

“Ordinary Resolution(s)”	the proposed ordinary resolution(s) as referred to in the notice of AGM
“Repurchase Mandate”	the general and unconditional mandate proposed to be granted to the Directors at the AGM to permit the repurchase of Shares of up to 10% of the issued share capital of the Company (excluding treasury shares of the Company, if any) as at the date of passing of the relevant resolution granting such mandate
“PRC”	the People’s Republic of China, which for the purpose of this circular, excludes Hong Kong, the Macau Special Administrative Region of PRC and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong)
“Shares”	the ordinary share(s) of US\$0.00000125 each in the capital of the Company (or of such nominal amount as shall result from a sub-division, consolidation, reclassification or reconstruction of the share capital of the Company from time to time)
“Shareholder(s)”	the holder(s) of the Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Share Option Schemes”	the share option schemes of the Company, including the share option scheme adopted by the Company on 22 October 2011 (amended by a unanimous written resolution of the Board on 5 May 2015), and terminated pursuant to an ordinary resolution passed by the Shareholders at a general meeting on 17 September 2021 and the new share option scheme adopted by the Company with effect from 17 September 2021
“Takeovers Code”	the Code on Takeovers and Mergers and Share Buy-backs issued by the Securities and Futures Commission, as amended from time to time
“%”	per cent.

*In this circular, the terms “close associate”, “core connected person”, “controlling shareholder”, “substantial shareholder” and “treasury shares” have the same meanings given to such terms in the Listing Rules, unless the context otherwise requires.*



**LIFETECH SCIENTIFIC CORPORATION**

**先健科技公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1302)**

*Executive Directors:*

XIE Yuehui (*Chairman and Chief Executive Officer*)

LIU Jianxiong (*Executive Vice President,  
Chief Financial Officer and Company Secretary*)

WU Liping

FANG Yu

FENG Xiaoling

*Non-executive Director:*

JIANG Feng

*Independent Non-executive Directors:*

ZHOU Luming

CHEN Dongxia

*Registered Office in Cayman Islands:*

PO Box 309

Ugland House

Grand Cayman, KY1-1104

Cayman Islands

*Principal place of business and  
address of headquarters:*

LifeTech Scientific Building,  
No. 22, Keji 12th Road South,  
High-tech Industrial Park,  
Nanshan District,  
Shenzhen 518063, PRC

*Place of business in Hong Kong  
registered under Part 16  
of the Hong Kong*

*Companies Ordinance:*  
31/F, 148 Electric Road,  
North Point,  
Hong Kong

6 May 2026

*To the Shareholders*

Dear Sir or Madam,

- (1) GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES**  
**(2) RE-ELECTION OF DIRECTORS AND CONTINUOUS APPOINTMENT OF  
INDEPENDENT NON-EXECUTIVE DIRECTOR**  
**(3) RE-APPOINTMENT OF AUDITORS**  
**AND**  
**(4) NOTICE OF ANNUAL GENERAL MEETING**

---

## LETTER FROM THE BOARD

---

### 1. INTRODUCTION

The purpose of this circular is to provide the Shareholders with information in relation to the resolutions to be proposed at the AGM in respect of the Issue Mandate and the Repurchase Mandate, the re-election of Directors and continuous appointment of independent non-executive Director who will have served for more than nine years, and to seek the Shareholders' approval of the resolutions relating to these matters at the AGM.

### 2. GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES

At the annual general meeting of the Company held on 28 May 2025, the General Mandates were granted to the Directors to issue and repurchase Shares respectively. Such mandates will lapse at the conclusion of the AGM.

At the AGM, an ordinary resolution will be proposed for the Shareholders to consider and, if thought fit, approve a new general mandate to the Directors to exercise the power of the Company to allot, issue or otherwise deal with additional Shares and to sell or transfer treasury shares of the Company (if any) as set out in Ordinary Resolution No. 4(A) up to a maximum of 20% of the issued share capital of the Company (excluding treasury shares of the Company, if any) as at the date of passing of the Ordinary Resolution No. 4(A) at the AGM.

At the AGM, an ordinary resolution will also be proposed for the Shareholders to consider and, if thought fit, approve a new general mandate to the Directors to exercise the power of the Company to repurchase Shares or securities convertible into Shares on the Stock Exchange or any other stock exchange of which the Shares may be listed and which is recognised by the Securities and Futures Commission and the Stock Exchange under the Codes on Takeovers and Mergers and Share Buy-backs as set out in Ordinary Resolution No. 4(B) up to a maximum of 10% of the issued share capital of the Company (excluding treasury shares of the Company, if any) as at the date of passing of the Ordinary Resolution No. 4(B) at the AGM. A resolution authorising the extension of the Issue Mandate to include the aggregate nominal amount of such securities (if any) repurchased under the Repurchase Mandate will be proposed as Ordinary Resolution No. 4(C) at the AGM.

The Issue Mandate and the Repurchase Mandate, if granted, will remain in effect until the earliest of (i) the conclusion of the next annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required by the Articles of Association or any applicable laws to be held; and (iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the Shareholders in general meeting.

As at the Latest Practicable Date, the issued share capital of the Company (excluding treasury shares of the Company, if any) comprised 4,631,712,400 fully paid up Shares. Assuming that there is no change in the issued share capital of the Company between the period from the Latest Practicable Date to the date of passing the resolution approving the Issue Mandate at the AGM, the maximum number of Shares which may be allotted and issued and treasury shares of the Company (if any) which may be sold and transferred by the Company pursuant to the Issue Mandate on the date of passing the resolution approving the Issue Mandate will be 926,342,480 Shares.

---

## LETTER FROM THE BOARD

---

An explanatory statement as required under Rule 10.06(1)(b) of the Listing Rules to provide the Shareholders with requisite information reasonably necessary for them to make an informed decision on whether to vote for or against the granting of the Repurchase Mandate is set out in Appendix I to this circular.

### **3. RE-ELECTION OF DIRECTORS AND CONTINUOUS APPOINTMENT OF MR. ZHOU LUMING AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR**

In accordance with the Articles of Association and following the review of the Board's composition by the Nomination Committee, Mr. XIE Yuehui, Mr. LIU Jianxiong, Ms. WU Liping, Mr. FANG Yu and Ms. FENG Xiaoling, Mr. JIANG Feng, Mr. ZHOU Luming and Ms. CHEN Dongxia shall retire from their offices as Directors at the forthcoming AGM. All the retiring Directors being eligible, will offer themselves for re-election as Directors.

The Nomination Committee has reviewed the structure and composition of the Board, the confirmations and disclosures given by the Directors, the qualifications, skills and experience, time commitment and contribution of the retiring Directors with reference to the prevailing nomination policy of the Company, the board diversity policy (including, without limitation, gender, age, cultural and educational background) and the Company's corporate strategy, and the independence of all retiring independent non-executive Directors. Mr. ZHOU Luming and Ms. CHEN Dongxia have confirmed their independence with reference to the factors set out in Rule 3.13 of the Listing Rules. As such, the Nomination Committee made recommendations to the Board regarding the re-election of the retiring Directors. The Board notes that the Directors for re-election have extensive experience in their fields and professions and their education, backgrounds, experience and practices allow them to bring valuable perspectives, insights and skills to the Board and contribute to the diversity thereof.

In addition, the Nomination Committee and the Board are not aware of any circumstance that might influence the independence of Mr. ZHOU Luming and Ms. CHEN Dongxia and considers Mr. ZHOU and Ms. CHEN to be independent. The Nomination Committee and the Board are satisfied that, taking into account, among others, the valuable insights, useful guidance and independent judgment provided to the Board by Mr. ZHOU and Ms. CHEN, they are of such character, integrity and experience commensurate with an office of an independent non-executive Director.

Mr. ZHOU Luming was appointed as an independent non-executive Director of the Company in 2014. As at the date of this circular, Mr. ZHOU Luming has served as an independent non-executive Director for more than nine years. Pursuant to the code provision B.2.3 of the Corporate Governance Code set out in Appendix C1 to the Listing Rules, if an independent non-executive director has served for more than nine years, his further appointment should be subject to a separate resolution to be approved by the Company's Shareholders. Pursuant to the code provision B.2.4 of the Corporate Governance Code set out in Appendix C1 to the Listing Rules, the Board is in the process of looking for and will appoint a new independent non-executive Director.

---

## LETTER FROM THE BOARD

---

The Company has received from Mr. ZHOU Luming a confirmation of independence according to Rule 3.13 of the Listing Rules and the Board has assessed and reviewed the independence of Mr. ZHOU based on the criteria set out in Rule 3.13 of the Listing Rules. Throughout his directorship with the Company, he has participated in Board meetings to give impartial advice and exercise independent judgement, served on various committees of the Board, but has never engaged in any executive management of the Group. Taking into consideration of his independent scope of work in the past years, the Board considers that the long service of Mr. ZHOU would not affect his exercise of independent judgement and is satisfied that Mr. ZHOU has the required character, integrity and experience to continue fulfilling the role of an independent non-executive Director. As such, the Directors consider Mr. ZHOU to be independent under the Listing Rules despite the fact that he has served the Company for more than nine years. The Board believes that Mr. ZHOU's continued tenure brings considerable stability to the Board and the Board has benefited greatly from the presence of Mr. ZHOU who has over time gained valuable insight into the Group.

At the AGM, ordinary resolutions will be proposed to re-elect all Directors, namely Mr. XIE Yuehui, Mr. LIU Jianxiong, Ms. WU Liping, Mr. FANG Yu, Ms. FENG Xiaoling, Mr. JIANG Feng, Mr. ZHOU Luming and Ms. CHEN Dongxia. The re-appointment of Mr. ZHOU at the AGM will be subject to a separate resolution to be approved by the Shareholders in accordance with the Listing Rules.

Biographical details on the retiring Directors proposed to be re-elected at the AGM are set out in Appendix II to this circular.

#### **4. RE-APPOINTMENT OF AUDITORS**

In accordance with Rule 13.88 of the Listing Rules, an ordinary resolution will be proposed at the AGM to re-appoint Messrs. Deloitte Touche Tohmatsu as the external auditors of the Company to hold office from the conclusion of the AGM until the next annual general meeting and to authorise the Board to fix their remuneration for the year ending 31 December 2026. The re-appointment of the auditors of the Company has been reviewed by the audit committee of the Company which made recommendation to the Board that the re-appointment be submitted and proposed for Shareholders' approval at the AGM.

As disclosed in the annual report of the Company for the financial year ended 31 December 2025, the remuneration paid/payable to the Company's external auditors of the Group in respect of audit services for the year amounted to RMB2.7 million.

When determining the fee in respect of audit services for the year ending 31 December 2026, the Company and its auditors will take into account a number of relevant factors, including complexity and business plan of the Company, the expected audit scope, audit timetable and auditors' resources required, and it is currently expected that, barring unforeseeable circumstances, the estimated audit fee would not be materially deviated from the audit fee for the year of 2025, subject to the relevant factors at the time.

---

## LETTER FROM THE BOARD

---

### 5. ANNUAL GENERAL MEETING

Set out on pages 21 to 25 of this circular is the notice convening the AGM at which, among other things, resolutions will be proposed to approve the Issue Mandate and the Repurchase Mandate, and the re-election of Directors and continuous appointment of independent non-executive Directors who has served for more than nine years. Pursuant to Rule 13.39(4) of the Listing Rules, any vote of the Shareholders at a general meeting of the Company must be taken by way of poll (except where the chairman of the meeting, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by show of hands). The chairman of the AGM will request for the resolutions to be considered (and, if thought fit, approved) at the AGM to be voted by way of poll by the Shareholders. An announcement on the poll results will be published by the Company after the AGM in the manner prescribed under Rule 13.39(5) of the Listing Rules.

A form of proxy for use at the AGM is enclosed with this circular. Whether or not you are able to attend the AGM in person, you are advised to complete the enclosed form of proxy in accordance with the instructions printed thereon as soon as possible and return the completed form of proxy to the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for holding the AGM or any adjournment thereof. Completion and return of the form of proxy will not preclude you from attending and voting in person at the AGM or any adjourned meeting if you so wish and in such event, the form of proxy shall be deemed to be revoked.

For the purpose of determining the identity of the Shareholders who are entitled to attend and vote at the AGM, the register of members of the Company will be closed from Friday, 22 May 2026 to Thursday, 28 May 2026, both days inclusive, during which period no transfer of shares of the Company will be effected. All transfers accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, by no later than 4:30 p.m. on Thursday, 21 May 2026.

### 6. RECOMMENDATIONS

The Board considers that the resolutions to be proposed at the AGM are all in the best interests of the Company and the Shareholders as a whole. Accordingly, the Board recommends all Shareholders to vote in favour of the relevant resolutions to be proposed at the AGM.

---

## LETTER FROM THE BOARD

---

### 7. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

Yours faithfully  
For and on behalf of the Board  
**LifeTech Scientific Corporation**  
**XIE Yuehui**  
*Executive Director, Chairman  
and Chief Executive Officer*

The following is the explanatory statement as required to be sent to the Shareholders under Rule 10.06(1)(b) of the Listing Rules for them to make an informed decision on whether to vote for or against the ordinary resolution to be proposed at the AGM in connection with the granting of the Repurchase Mandate.

### **1. THE REPURCHASE AND SHARE CAPITAL**

The resolution set out as Ordinary Resolution No. 4(B) relates to the granting of a general and unconditional mandate to the Directors to repurchase, on the Stock Exchange or any other stock exchange on which the Shares of the Company may be listed and recognised by The Securities and Futures Commission of Hong Kong, Shares or securities convertible into Shares of up to a maximum of 10% of the issued share capital of the Company as at the date of the passing of the relevant resolution.

As at the Latest Practicable Date, the issued share capital of the Company comprised 4,631,712,400 Shares. Subject to the passing of the resolution granting the Repurchase Mandate and on the basis that no further Shares are issued or repurchased after the Latest Practicable Date and up to the date of the AGM, the Company will be allowed to repurchase a maximum of 463,171,240 Shares (excluding treasury shares of the Company, if any) during the period ending on the earliest of (i) the conclusion of the next annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required by any applicable laws or the Articles of Association to be held; or (iii) the date on which such authority is revoked or varied by an ordinary resolution of the Shareholders in general meeting.

### **2. REASONS FOR REPURCHASE**

Although the Directors have no present intention of repurchasing the Shares, they believe that it is in the interests of the Company and the Shareholders as a whole for the Directors to have a general authority from the Shareholders to enable the Company to repurchase Shares on the market. Such repurchases may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the net assets value of the Company and/or its earnings per Share and will only be made when the Directors believe that such repurchases will benefit the Company and the Shareholders as a whole.

### **3. FUNDING OF REPURCHASE**

In repurchasing Shares, the Company may only apply funds legally available for such purpose in accordance with the Articles of Association, the Listing Rules and the applicable laws and regulations of the Cayman Islands.

The Company shall not repurchase its own Shares on the Stock Exchange for a consideration other than cash or for settlement otherwise than in accordance with the trading rules of the Stock Exchange from time to time.

Subject to the above, any repurchase of the Shares by the Company may be made out of profits of the Company or out of a fresh issue of Shares made for the purpose of the repurchase or subject to Companies Act, out of capital provided that on the day immediately following the date of repurchase of the Shares, the Company is able to pay its debts as they fall due in the ordinary course of business.

#### 4. IMPACT OF REPURCHASE

There may be a material adverse impact on the working capital or gearing position of the Company as compared with the financial position of the Company as at 31 December 2025 (being the date of its latest audited accounts) if the Repurchase Mandate were to be exercised in full at the current prevailing market value at any time during the proposed purchase period. However, the Directors will not exercise the Repurchase Mandate to such extent as would, in the circumstances, have a material adverse effect on the working capital or the gearing level (as compared with the position disclosed in its most recent published audited accounts) which in the opinion of the Directors are, from time to time, inappropriate for the Company. The Company had no intention to repurchase any Shares as at the Latest Practicable Date.

The Company may cancel any Shares it repurchased and/or hold them as treasury shares subject to market conditions and the Group's capital management needs at the relevant time of the repurchases.

#### 5. SHARE PRICES

The highest and lowest prices at which the Shares were traded on the Stock Exchange during each of the twelve months preceding the Latest Practicable Date were as follows:

Month	Price per Share	
	Highest HK\$	Lowest HK\$
<b>2025</b>		
March	1.73	1.50
April	1.71	1.26
May	1.71	1.41
June	2.13	1.50
July	2.15	1.70
August	2.33	1.93
September	2.07	1.74
October	2.44	1.88
November	2.08	1.78
December	2.00	1.47
<b>2026</b>		
January	1.90	1.52
February	1.83	1.60
March	1.79	1.55
April (up to the Latest Practicable Date)	2.24	1.70

**6. GENERAL INFORMATION**

None of the Directors, and, to the best of their knowledge of the Directors having made all reasonable enquires, none of the close associates of the Directors, has any present intention to sell any Shares to the Company or any of its subsidiaries, if the Repurchase Mandate is approved by the Shareholders.

No core connected person of the Company has notified the Company that he has a present intention to sell any Shares to the Company, or has undertaken not to do so, in the event that the Repurchase Mandate is approved by the Shareholders.

The Directors will exercise the power of the Company to make repurchases of Shares pursuant to the Repurchase Mandate, if granted, in accordance with the Listing Rules, the applicable laws of the Cayman Islands and the regulations set out in the Articles of Association. Neither this explanatory statement nor the proposed repurchase of Shares has any unusual features.

**7. TAKEOVERS CODE**

If as a result of a repurchase of Shares, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition for the purposes of Rule 32 of the Takeovers Code.

Accordingly, a Shareholder, or a group of Shareholders acting in concert (as defined in the Takeovers Code), depending on the level of increase of the Shareholders' interest, could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rules 26 of the Takeovers Code.

As at the Latest Practicable Date and to the best knowledge of the Directors, the single largest substantial shareholder (as defined under Listing Rules) of the Company, Xianjian Advanced Technology Limited was beneficially interested in 464,194,928 Shares representing approximately 10.02% of the total issued share capital of the Company. In the event that the Directors exercise in full the power to repurchase Shares in accordance with the Repurchase Mandate, the interest of the largest substantial shareholder of the Company would be increased to approximately 11.13% of the total issued share capital of the Company. Such increase will not give rise to an obligation to make a mandatory offer under Rules 26 and 32 of the Takeovers Code. The Directors will be cautious in exercising the Repurchase Mandate. The Board has no intention to repurchase Shares in a manner that would trigger a mandatory general offer obligation on the part of the above person or otherwise would result in the number of Shares held by the public being reduced to less than the minimum public float requirement as prescribed under the Listing Rules.

**8. REPURCHASE OF SHARES MADE BY THE COMPANY**

The Company had not repurchased any Shares (whether on the Stock Exchange or otherwise) in the six months' period preceding the Latest Practicable Date.

This appendix contains the biographical details of the Directors eligible for re-election at the AGM to enable the Shareholders to make an informed view on whether to vote for or against the resolution to be proposed at the AGM in relation to the re-election of Directors.

### **Executive Directors**

**XIE Yuehui (謝粵輝)**, aged 56, is the chairman, Chief Executive Officer and an executive Director. Mr. XIE has served as the director of Lifetech Shenzhen since October 2000 and was promoted to serve as the chairman of Lifetech Shenzhen since 2005. Mr. XIE was appointed as a director of three overseas subsidiaries and 10 PRC subsidiaries or associates of the Group successively since 2013. Mr. XIE is primarily responsible for the Group's overall strategic planning and the management of the Group's business. Mr. XIE has about 35 years of experience in business management in the PRC, including over 23 years in the medical device industry. In June 2015, Mr. XIE was appointed as a representative of the Sixth Shenzhen Municipal People's Congress. From 1991 to 1993, Mr. XIE served as the project manager of Eastern Tantalum Group (東方鉭業集團). From June 1993 to January 1994, Mr. XIE was the investment manager at a subsidiary of China Southern Securities (南方證券), and was responsible for project investment. From February 1994 to February 1996, Mr. XIE held the position of the deputy general manager at an investment branch of Bank of China, Jilin Province, and was responsible for managing futures investment projects. From February 1996 to December 1998, Mr. XIE served as the manager at the domestic trade department of Shenzhen Huihua Group (深圳市匯華集團) and was responsible for overall trade management. Since June 1998, Mr. XIE was a general manager at Shenzhen Huishibang Technology Company Limited (深圳市匯世邦科技有限公司) and was promoted to its chairman in 2000. During this period, Mr. XIE was responsible for overall business management. Mr. XIE graduated from Kunming Institute of Technology (昆明工學院) in July 1991 with a bachelor's degree in materials specialising in pressurised processing of metals (金屬壓力加工專業). He also obtained a master's degree in business administration from Tsinghua University in July 2006.

Save as disclosed above, Mr. XIE does not hold any directorship in any other public companies the securities of which are listed in Hong Kong or overseas in the past three years. In addition, Mr. XIE does not have any relationship with any other Directors, senior management or substantial shareholders or controlling shareholders of the Company.

Mr. XIE has signed a service contract with the Company for an initial term of three years commencing from 10 November 2011, which is subject to automatic renewal every three years on the same terms and conditions until terminated by either party giving to the other party not less than three months' notice in writing. On 10 November 2014, 10 November 2017, 10 November 2020 and 10 November 2023, Mr. XIE and the Company renewed the service contract which is subject to manual renewal every three years. Pursuant to the terms of his service contract and as determined by the Board, Mr. XIE was entitled to an annual emolument of RMB12,150,000 (including discretionary performance bonus and all other benefits) and nil director's fee for the financial year ended 31 December 2025.

As at the Latest Practicable Date, Mr. XIE is interested in 468,794,928 Shares within the meaning of Part XV of the SFO, including 4,600,000 share options of the Company, which were granted subject to certain vesting conditions pursuant to the Share Option Schemes.

Save as disclosed above, there are no other matters concerning Mr. XIE that need to be brought to the attention of the Shareholders, nor is there any information required to be disclosed pursuant to the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

**LIU Jianxiong (劉劍雄)**, aged 55, is the Executive Vice President, Chief Financial Officer, Company Secretary and an executive Director. He was appointed as a non-executive Director on 2 March 2015 and was subsequently re-designated as an executive Director with effect from 27 March 2015. On 13 July 2017, he was promoted to serve as Vice President. On 12 April 2019, he was further promoted to serve as Executive Vice President. Mr. LIU joined the Group in September 2010 and he has been appointed as a director of a number of the Company's subsidiaries, including LifeTech Scientific (Europe) B.V., LifeTech Scientific (Netherlands) B.V., Dongguan LifeTech-Quantum Medical Technology Co., Ltd., Lifetech Scientific America Corporation, LifeTech Scientific International Holding Limited and Shenzhen Lvdong Electrophysiology Technology Co., Ltd. (深圳律動電生理科技有限公司) successively since 2015. Mr. LIU was also appointed as the supervisor of Shenzhen LifeTech Innovation Medical Investment Co., Ltd. (深圳市先健創新醫療投資有限公司) in 2020. Mr. LIU has about 33 years of experience in the accounting field. He started his career as an auditor at Kwan Wong Tan & Fong (currently Deloitte Touche Tohmatsu) in 1993, and was primarily responsible for carrying out audits and consultancy work. Mr. LIU then continued to work with a number of multinational companies. From 1997 to 2001, he was the accounting services manager of Yantian International Container Terminal Company Limited (鹽田國際集裝箱碼頭有限公司). From 2001 to 2003, Mr. LIU was the financial controller of Shenzhen Schlumberger Electronic System Solution Co., Ltd. (深圳斯倫具謝電子系統有限公司). From March 2007 to July 2007, Mr. LIU was the China financial controller of China Light & Power Group's renewable energy division. From December 2007 to February 2010, Mr. LIU was the corporate controller of AnyDATA Group in the Great China, and was responsible for financial management, accounts audit, tax planning, raising capital and preparation of financial accounts in accordance with accounting standards in PRC, U.S. and Hong Kong. He has been a member of the Association of Chartered Certified Accountants since 1997 and a registered tax agent since 1999. Mr. LIU graduated from Zhongshan University's faculty of physics with a major in modern physics technology in July 1990. He obtained a master's degree in business administration from University of Glamorgan in the United Kingdom in December 2004.

Save as disclosed above, Mr. LIU does not hold any directorship in any other public companies the securities of which are listed in Hong Kong or overseas in the past three years. In addition, Mr. LIU does not have any relationship with any other Directors, senior management or substantial shareholders or controlling shareholders of the Company.

Mr. LIU has signed a service contract with the Company for an initial term of three years commencing from 27 March 2015, which is subject to automatic renewal every three years until terminated by either party giving to the other party not less than three months' notice in writing. On 27 March 2018 and 27 March 2021 and 27 March 2024, Mr. LIU and the Company renewed the service contract which is subject to manual renewal every three years. Pursuant to the terms of his service contract and as determined by the Board, Mr. LIU was entitled to an annual emolument of RMB20,586,000 (including discretionary performance bonus and all other benefits) and nil director's fee for the financial year ended 31 December 2025.

As at the Latest Practicable Date, Mr. LIU is interested in 69,458,000 Shares within the meaning of Part XV of the SFO which includes 36,000,000 share options of the Company, which were granted subject to certain vesting conditions pursuant to the Share Option Schemes.

Save as disclosed above, there are no other matters concerning Mr. LIU that need to be brought to the attention of the Shareholders, nor is there any information required to be disclosed pursuant to the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

**WU Liping (吳麗萍)**, aged 45, was appointed as an executive Director with effect from 21 November 2025. Ms. WU holds a bachelor's degree and is currently pursuing an EMBA at the University of Hong Kong — Peking University. Ms. WU has been deeply engaged in the field of vascular minimally invasive therapy for over 20 years. Since joining the Group in 2006, she has established the market systems and product portfolio for the aortic and peripheral vascular businesses of the Group. Ms. WU is currently serving as the vice president of the Group, where she is responsible for the overall operation, management, strategy formulation and execution of the comprehensive pan-vascular business segment. She also holds directorships, legal representative roles, and senior management positions in several of the Group's subsidiaries and joint ventures. During her tenure, Ms. WU spearheaded the research and development, clinical registration, market access, and commercialisation strategies for multiple innovative medical devices. She has been instrumental in driving the transformation of the Group's aortic business from a single-product focus towards offering integrated pan-vascular solutions. Ms. WU has achieved several breakthroughs in aortic endovascular treatment innovations and the commercialisation of domestically developed high-end medical devices. She pioneered the Group's strategic expansion into new pan-vascular sectors, propelling the sustained development and scalable growth of the peripheral vascular business. Concurrently, she accelerated the Group's collaboration and capability building in industry-academia-research initiatives, leading synergistic partnerships with numerous universities and clinical institutions. These efforts have substantially strengthened the Group's foundational capabilities in original product innovation, clinical demand translation, and cross-disciplinary collaboration. Ms. WU was awarded the First Prize of the 2024 Chinese Medical Science and Technology Award and the First Prize of the 2024 Military Science and Technology Progress Award. She holds several relevant invention patents and consecutively received the Shenzhen Industrial Development and Innovation Talent Award from 2019 to 2021. She also serves as a committee member of the vascular surgery branch of the Jiangsu Research Hospital Association and acts as an external postgraduate supervisor for the Textiles College of Donghua University.

Save as disclosed above, Ms. WU does not hold any directorship in any other public companies the securities of which are listed in Hong Kong or overseas in the past three years. In addition, Ms. WU does not have any relationship with any other Directors, senior management or substantial shareholders or controlling shareholders of the Company.

Ms. WU has been appointed as executive Directors and entered into service contracts with the Company for an initial term of three years commencing from 21 November 2025 until terminated by either party giving to the other party not less than three months' notice in writing. Pursuant to the terms of her service contract and as determined by the Board, Ms. WU was entitled to a monthly emolument of RMB 155,732 (excluding discretionary performance bonus and all other benefits) and nil director's fee for the financial year ended 31 December 2025.

As at the Latest Practicable Date, Ms. WU is interested in 60,870,000 Shares within the meaning of Part XV of the SFO which includes 23,040,000 share options of the Company, which were granted subject to certain vesting conditions pursuant to the Share Option Schemes of the Company.

Save as disclosed above, there are no other matters concerning Ms. WU that need to be brought to the attention of the Shareholders, nor is there any information required to be disclosed pursuant to the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

**FANG Yu (方宇)**, aged 47, was appointed as an executive Director with effect from 21 November 2025. Mr. FANG holds a bachelor's and master's degree in Polymer Materials Science and Engineering from Tsinghua University. Mr. FANG has over 20 years of experience in the medical device industry. Mr. FANG currently serves as the vice president of the Group, where he is primarily responsible for the overall coordination and strategic execution of the structural heart diseases and electrophysiology business. Mr. FANG also serves as a chairman, director, supervisor, legal representative and senior management of various subsidiaries, associates and joint ventures of the Group. Since assuming his current position in the Group in 2016, he has led the structural heart department to achieve rapid sales growth, spearheaded the comprehensive market launch and promotion of the Group's Left Atrial Appendage Occluder, and driven improvements and optimisation of existing products while exploring new business areas and incubating new products. Mr. FANG possesses extensive project management expertise and innovation capability, holds several relevant invention patents, and consecutively received the Shenzhen Industrial Development and Innovation Talent Award from 2019 to 2021. Prior to joining the Group, he worked at Johnson & Johnson (Shanghai) Medical Devices Limited and St. Jude Medical (Shanghai) Co., Ltd.

Save as disclosed above, Mr. FANG does not hold any directorship in any other public companies the securities of which are listed in Hong Kong or overseas in the past three years. In addition, Mr. FANG does not have any relationship with any other Directors, senior management or substantial shareholders or controlling shareholders of the Company.

Mr. FANG has been appointed as executive Directors and entered into service contracts with the Company for an initial term of three years commencing from 21 November 2025 until terminated by

either party giving to the other party not less than three months' notice in writing. Pursuant to the terms of his service contract and as determined by the Board, Mr. FANG was entitled to a monthly emolument of RMB 150,053 (excluding discretionary performance bonus and all other benefits) and nil director's fee for the financial year ended 31 December 2025.

As at the Latest Practicable Date, Mr. FANG is interested in 49,700,000 Shares within the meaning of Part XV of the SFO which includes 17,700,000 share options of the Company, which were granted subject to certain vesting conditions pursuant to the Share Option Schemes of the Company.

Save as disclosed above, there are no other matters concerning Mr. FANG that need to be brought to the attention of the Shareholders, nor is there any information required to be disclosed pursuant to the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

**FENG Xiaoling (馮小玲)**, aged 54, was appointed as an executive Director with effect from 21 November 2025. Ms. FENG holds a MBA from the Shanghai University of Finance and Economics and has over 25 years of corporate management experience, with notable achievements in international business expansion. Ms. FENG currently serves as the vice president of the Group, with responsibility for the Group's international market development, cross-border business cooperation, and global resource integration. Ms. FENG also serves as a director, legal representative and senior management of various subsidiaries, associates and joint ventures of the Group. Since joining the Group in 2017, she has successfully led the establishment of an in-depth market network in over 100 countries and regions worldwide, driving the international commercialisation of multiple innovative medical device products. Under her leadership, the Group's international layout has become increasingly robust, with global subsidiaries and offices developing synergistically and the sales network continuously expanding, significantly enhancing the Group's brand influence and competitiveness in the international market. Prior to joining the Group, Ms. FENG held senior executive positions at several multinational corporations.

Save as disclosed above, Ms. FENG does not hold any directorship in any other public companies the securities of which are listed in Hong Kong or overseas in the past three years. In addition, Ms. FENG does not have any relationship with any other Directors, senior management or substantial shareholders or controlling shareholders of the Company.

Ms. FENG has been appointed as executive Directors and entered into service contracts with the Company for an initial term of three years commencing from 21 November 2025 until terminated by either party giving to the other party not less than three months' notice in writing. Pursuant to the terms of her service contract and as determined by the Board, Ms. FENG was entitled to a monthly emolument of RMB 140,495 (excluding discretionary performance bonus and all other benefits) and nil director's fee for the financial year ended 31 December 2025.

As at the Latest Practicable Date, Ms. FENG is interested in 56,114,338 Shares within the meaning of Part XV of the SFO which includes 18,100,000 share options of the Company, which were granted subject to certain vesting conditions pursuant to the Share Option Schemes of the Company.

Save as disclosed above, there are no other matters concerning Ms. FENG that need to be brought to the attention of the Shareholders, nor is there any information required to be disclosed pursuant to the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

**Non-executive Director**

**JIANG Feng (姜峰)**, aged 63, was appointed as a non-executive Director on 1 April 2014. Mr. JIANG is currently vice president of China Association for Medical Devices Industry, chairman of China Strategic Alliance of Medical Devices Innovation, deputy director of Biomedical Engineering Education Steering Committee of the Ministry of Education (教育部生物醫學工程專業教育指導委員會) and chairman of TC94 sub-committee of National Standards Technical Committee (國家標準技術委員會). Mr. JIANG had been working as a clinician for 12 years before he left the hospital in 1997 to establish his own business. For his outstanding achievements, Mr. JIANG was considered to be special talent by SASAC and was chosen to be a leader of national large medicine and device companies for a long term, including as chairman and general manager of China National Pharmaceutical Group Corporation North West Company and China National Medical Equipment Co., Ltd.. During that period, Mr. JIANG was in charge of or participated in restructuring, mergers and acquisitions and transformations for the listing of nearly 40 relevant companies. Mr. JIANG served as a general manager of China National Medical Equipment Co., Ltd. for 9 years, during which he accomplished the substantial transformation of the enterprise from an exhibition business to the production and operation of medical devices by establishing China's first Sino-foreign joint venture medical device distribution company and making it the largest domestic medical device distributor within 5 years. Mr. JIANG had been president and standing vice president of China Association for Medical Devices Industry for 23 years, during which he visited and evaluated over a thousand of member enterprises. For around 16 years as a chairman of China Strategic Alliance of Medical Devices Innovation, he has been assisting the science and technology department and local science and technology bureaus in assessing subjects of hundreds of medical device projects and conducting subsequent management. Benefiting from his extensive work experience in the industry, Mr. JIANG is expert at the operation and management of medical companies and understands development trends of the industry, particularly in industrial innovation and international marketing. Since 8 November 2016, Mr. JIANG was appointed as an independent non-executive director of Hangzhou Kangji Medical Instrument Co., Ltd. for a term of three years. Since December 2022, Mr. JIANG was appointed as an independent director of Dynamiker Biotechnology (Tianjin) Co., Ltd. and resigned in June 2023. Since April 2023, Mr. JIANG has been appointed as an independent director of SWS Hemodialysis Care Co., Ltd.. Since September 2023, Mr. JIANG has been appointed as an independent director of Inkon Life Technology Co., Ltd.. Mr. JIANG graduated from the Fourth Military Medical University with a bachelor's degree in Medicine in 1985 and obtained his doctoral degree in clinical surgery in 1995 from the Fourth Military Medical University. He obtained an EMBA degree from Tsinghua University in 2007.

Save as disclosed above, Mr. JIANG does not hold any directorship in any other public companies the securities of which are listed in Hong Kong or overseas in the past three years. In addition, Mr. JIANG does not have any relationship with any other Directors, senior management or substantial shareholders or controlling shareholders of the Company.

The Company and Mr. JIANG entered into an appointment letter on 1 April 2014 with a term of three years subject to retirement by rotation and re-election at the next following annual general meeting of the Company pursuant to the Articles of Association, the Listing Rules and any other applicable laws and regulations. On 1 April 2017, Mr. JIANG and the Company renewed the appointment letter which is subject to manual renewal every three years. On 26 April 2019, 26 April 2022 and 26 April 2025, Mr. JIANG further renewed the appointment letters with the Company which is subject to manual renewal every three years. Remuneration and allowances will be determined by the Board with reference to his contribution in terms of time, effort, experience and his expertise. Pursuant to the terms of his appointment letter contract and as determined by the Board, Mr. JIANG was entitled to an emolument of RMB180,000 for the financial year ended 31 December 2025.

As at the Latest Practicable Date, Mr. JIANG does not have any interest, deemed interest or short positions in any Shares, underlying Shares or debentures of the Company and its associated corporations pursuant to Part XV of the SFO.

Save as disclosed above, there are no other matters concerning Mr. JIANG that need to be brought to the attention of the Shareholders of the Company, nor is there any information required to be disclosed pursuant to the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

#### **Independent Non-executive Directors**

**ZHOU Luming** (周路明), aged 67, was appointed as an independent non-executive Director with effect from 1 April 2014. Mr. ZHOU is currently the president of the Shenzhen CRI Innovation Center (深圳市源創力離岸創新中心) and the chairman of Shenzhen CRI Qingyuan Investment Management Co., Ltd. (深圳市源創力清源投資管理有限公司). He was a teacher in South-Central Minzu University from July 1984 to May 1992. During that period, he published a professional work titled Systems Science (系統科學) together with a number of academic papers. From May 1992 to September 2001, he worked in the Shenzhen Technology Bureau (深圳市科技局) as the head of the compliance division, director of general office and head of the planning division, taking charge of the establishment of a series of major legislations and research on decision-making work. Mr. ZHOU acted as deputy dean of the Research Institute of Tsinghua University in Shenzhen from September 2001 to May 2004. He was deputy director of the Shenzhen Technology Bureau from May 2004 to May 2008. During the period from 2005 to 2008, Mr. ZHOU presided over series of study on innovative cities. From 2008 to March 2014, when he served as chairman of the Shenzhen Science and Technology Association, he established a great number of private-funded research institutes of international advanced level, which involved metamaterial, new energy and precise manufacturing. His experience in directing the restructuring of the Shenzhen Science and Technology Association was highly appreciated by major leaders of the China Association of Science and Technology and was promoted within the system of the associations of science and technology. Mr. ZHOU graduated from the Faculty of Physics of Central China Normal University in 1984, and obtained his EMBA degree after graduating from Tsinghua University in 2005.

Save as disclosed above, Mr. ZHOU does not hold any directorship in any other public companies the securities of which are listed in Hong Kong or overseas in the past three years. In addition, Mr. ZHOU does not have any relationship with any other Directors, senior management or substantial shareholders or controlling shareholders of the Company.

The Company and Mr. ZHOU entered into an appointment letter on 1 April 2014 with a term of one year, subject to retirement by rotation and re-election at the next following annual general meeting of the Company pursuant to the Articles of Association, the Listing Rules and any other applicable laws and regulations. On 10 November 2014, Mr. ZHOU and the Company renewed the appointment letter which is subject to manual renewal every three years. On 1 April 2017, Mr. ZHOU and the Company renewed the appointment letter which is subject to manual renewal every three years. On 26 April 2019, 26 April 2022 and 26 April 2025, Mr. Zhou further renewed the appointment letters with the Company which is subject to manual renewal every three years. Remuneration and allowances will be determined by the Board with reference to his contribution in terms of time, effort, experience and his expertise. Pursuant to the terms of his appointment letter and as determined by the Board, Mr. ZHOU was entitled to an emolument of RMB180,000 for the financial year ended 31 December 2025.

As at the Latest Practicable Date, Mr. ZHOU does not have any interest, deemed interest or short positions in any Shares, underlying Shares or debentures of the Company and its associated corporations pursuant to Part XV of the SFO.

Save as disclosed above, there are no other matters concerning Mr. ZHOU that need to be brought to the attention of the Shareholders of the Company, nor is there any information required to be disclosed pursuant to the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

**CHEN Dongxia** (陳東霞), aged 49, was appointed as an independent non-executive Director with effect from 21 November 2025. Ms. CHEN is a senior professional in financial investment and asset management with over 20 years of experience in cross-border capital operations and merger and acquisition investments. She holds dual bachelor's degrees in Accounting and International Business from Jinan University in China, as well as a master's degree in Accounting and Finance from the University of Sydney in Australia. She also holds professional qualifications including CFA, FCPA, and ESG Investing and Virtual Asset Professional and is licensed by the Hong Kong Securities and Futures Commission as a Responsible Officer (RO) for Type 4 (Advising on Securities) and Type 9 (Asset Management) regulated activities. Ms. CHEN is currently the Council Member of the Hong Kong China Financial Association, she served as Deputy General Manager of Taiping Financial Holdings Company Ltd, Deputy General Manager of China Resources Healthcare Group Limited, Deputy General Manager of the Finance Department of China Resources Group, and General Manager of Finance at CR Capital. She has extensive experience in asset allocation, cross-border investments, mergers and acquisitions, and private equity funds, and has led multiple major capital transactions and the establishment and fundraising of various private equity funds. Ms. CHEN is fluent in both Chinese and English, well-versed in diverse capital market environments, and brings both an international perspective and strong localized execution capabilities.

Save as disclosed above, Ms. CHEN does not hold any directorship in any other public companies the securities of which are listed in Hong Kong or overseas in the past three years. In addition, Ms. CHEN does not have any relationship with any other Directors, senior management or substantial shareholders or controlling shareholders of the Company.

The Company and Ms. CHEN entered into an appointment letter on 21 November 2025 with a term of three years, subject to retirement by rotation and re-election at the next following annual general meeting of the Company pursuant to the Articles of Association, the Listing Rules and any other applicable laws and regulations. Remuneration and allowances will be determined by the Board with reference to her contribution in terms of time, effort, experience and her expertise. Pursuant to the terms of her appointment letter and as determined by the Board, Ms. CHEN was entitled to an emolument of RMB20,000 for the financial year ended 31 December 2025.

As at the Latest Practicable Date, Ms. CHEN does not have any interest, deemed interest or short positions in any Shares, underlying Shares or debentures of the Company and its associated corporations pursuant to Part XV of the SFO.

Save as disclosed above, there are no other matters concerning Ms. CHEN that need to be brought to the attention of the Shareholders of the Company, nor is there any information required to be disclosed pursuant to the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

---

## NOTICE OF ANNUAL GENERAL MEETING

---



### LIFETECH SCIENTIFIC CORPORATION

### 先健科技公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1302)**

### NOTICE OF ANNUAL GENERAL MEETING

**NOTICE IS HEREBY GIVEN** that the annual general meeting of LifeTech Scientific Corporation (先健科技公司) (the “**Company**”) will be held at Floor 16, LifeTech Scientific Building, No. 22, Keji 12th Road South, High-tech Park, Nanshan District, Shenzhen, PRC on Thursday, 28 May 2026 at 10:00 a.m. for the following purposes:

As ordinary business:

1. To consider and adopt the audited consolidated financial statements of the Company and its subsidiaries for the year ended 31 December 2025 and the reports of the directors of the Company (the “**Directors**”) and of the independent auditor;
2.
  - (i) To re-elect Mr. XIE Yuehui as an executive Director;
  - (ii) To re-elect Mr. LIU Jianxiong as an executive Director;
  - (iii) To re-elect Ms. WU Liping as an executive Director;
  - (iv) To re-elect Mr. FANG Yu as an executive Director;
  - (v) To re-elect Ms. FENG Xiaoling as an executive Director;
  - (vi) To re-elect Mr. JIANG Feng as a non-executive Director;
  - (vii) To re-elect, approve, and confirm Mr. ZHOU Luming as an independent non-executive Director who has served the Company for more than nine years as an independent non-executive Director;
  - (viii) To re-elect Ms. CHEN Dongxia as an independent non-executive Director; and
  - (ix) To authorize the board of Directors (the “**Board**”) to fix the Directors’ remuneration;

---

## NOTICE OF ANNUAL GENERAL MEETING

---

3. To re-appoint Deloitte Touche Tohmatsu as the auditors of the Company and to authorize the Board to fix its remuneration;

As additional ordinary business, to consider and, if thought fit, passing the following resolutions, with or without amendments, as ordinary resolutions:

4. (A) **“THAT:**
  - (a) subject to sub-paragraph (c) of this resolution, the exercise by the Directors during the Relevant Period (as hereinafter defined) of all the powers of the Company to allot, issue or otherwise deal with additional shares of the Company (the **“Shares”**) or securities convertible into Shares, or options, warrants or similar rights to subscribe for any Shares and to sell and transfer any treasury shares of the Company and to make or grant offers, agreements and options which might require the exercise of such powers be and is hereby generally and unconditionally approved;
  - (b) the approval in sub-paragraph (a) of this resolution shall authorize the Directors during the Relevant Period to make or grant offers, agreements and options which might require the exercise of such powers after the end of the Relevant Period;
  - (c) the aggregate nominal amount of share capital to be allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to an option or otherwise) by the Directors pursuant to the approval given in sub-paragraph (a) of this resolution, otherwise than pursuant to (i) a Rights Issue (as hereinafter defined), or (ii) the exercise of rights of subscription or conversion under the terms of any warrants issued by the Company or any securities which are convertible into Shares, or (iii) the exercise of any options granted under any option scheme or similar arrangement for the time being adopted for the grant or issue to officers and/or employees of the Company and/or any of its subsidiaries of Shares or rights to acquire Shares, or (iv) any scrip dividend or similar arrangement providing for the allotment of Shares in lieu of the whole or part of a dividend on Shares in accordance with the memorandum and articles of association of the Company (the **“Articles of Association”**), shall not exceed 20% of the aggregate nominal amount of the share capital of the Company in issue (excluding treasury shares of the Company, if any) as at the date of the passing of this resolution, and the said approval shall be limited accordingly;
  - (d) subject to the passing of each of the paragraphs (a), (b) and (c) of this resolution, any prior approvals of the kind referred to in paragraphs (a), (b) and (c) of this resolution which had been granted to the Directors and which are still in effect be and are hereby revoked; and
  - (e) for the purposes of this resolution:

**“Relevant Period”** means the period from the passing of this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company;

---

## NOTICE OF ANNUAL GENERAL MEETING

---

- (ii) the expiration of the period within which the next annual general meeting of the Company is required by the Articles of Association or any applicable laws to be held; and
- (iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders of the Company in general meeting.

“**Rights Issue**” means an offer of Shares in the share capital of the Company or an offer or issue of warrants or options or similar instruments or other securities giving the right to subscribe for Shares open for a period fixed by the Directors to holders of Shares or any class thereof, on the register of members of the Company on a fixed record date in proportion to their then holdings of such Shares or class thereof (subject to such exclusion or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of, or the requirements of, or the expense or delay which may be involved in determining the existence or extent of any restrictions or obligations under the laws of, or the requirements of, any jurisdiction applicable to the Company, or any recognised regulatory body or any stock exchange applicable to the Company).”

4. (B) “**THAT:**

- (a) subject to sub-paragraph (b) of this resolution, the exercise by the Directors during the Relevant Period (as hereinafter defined) of all the powers of the Company to repurchase Shares or securities convertible into Shares on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) or on any other stock exchange of which the Shares may be listed and which is recognised by the Securities and Futures Commission and the Stock Exchange under the Codes on Takeovers and Mergers and Share Buy-backs, subject to and in accordance with all the applicable laws, rules and regulations, be and is hereby generally and unconditionally approved;
- (b) the aggregate nominal amount of the securities of the Company which may be repurchased pursuant to the approval in sub-paragraph (a) of this resolution during the Relevant Period shall not exceed 10% of the aggregate nominal amount of the share capital of the Company in issue (excluding treasury shares of the Company, if any) as at the date of the passing of this resolution and the said approval shall be limited accordingly;
- (c) subject to the passing of each of the paragraphs (a) and (b) of this resolution, any prior approvals of the kind referred to in paragraphs (a) and (b) of this resolution which had been granted to the Directors and which are still in effect be and are hereby revoked; and
- (d) for the purposes of this Resolution:

“**Relevant Period**” shall have the same meaning as ascribed to it under sub-paragraph (d) of resolution No. 4(A) set out in the notice convening this meeting.”

---

## NOTICE OF ANNUAL GENERAL MEETING

---

As special business, to consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

4. (C) “**THAT** conditional upon resolutions Nos. 4(A) and 4(B) set out in the notice convening this meeting being passed, the general mandate granted to the Directors to exercise the powers of the Company to allot, issue or otherwise deal with the Shares and to sell and transfer any treasury shares of the Company pursuant to resolution No. 4(A) above be and is hereby extended by the addition to the aggregate nominal amount of the Shares of an amount representing the aggregate nominal amount of the share capital repurchased by the Company after the date of the passing of this resolution under the authority granted pursuant to resolution No. 4(B) above (up to a maximum of 10% of the aggregate nominal amount of the share capital of the Company in issue (excluding treasury shares of the Company, if any) as at the date of the passing of this resolution).”

By Order of the Board  
**LifeTech Scientific Corporation**  
**XIE Yuehui**  
*Executive Director, Chairman  
and Chief Executive Officer*

Hong Kong, 6 May 2026

*Notes:*

- (1) *All resolutions (except for procedural and administrative matters) at the meeting will be taken by poll pursuant to the Rules Governing the Listing of Securities on the Stock Exchange (the “Listing Rules”). The results of the poll will be published on the websites of Hong Kong Exchanges and Clearing Limited and the Company in accordance with the Listing Rules.*
- (2) *Any member entitled to attend and vote at the meeting convened by the above notice is entitled to appoint one or, if he is the holder of two or more shares, more proxies to attend and, subject to the provisions of the Articles of Association, vote in his stead. A proxy need not be a member of the Company. If more than one proxy is so appointed, the appointment shall specify the number and class of shares in respect of each such proxy is so appointed.*
- (3) *In order to be valid, the form of proxy must be deposited together with a power of attorney or other authority, if any, under which it is signed or a notarially certified copy of that power or authority, at the Company’s branch share registrar in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not less than 48 hours before the time appointed for the holding of the meeting or any adjournment thereof. Delivery of an instrument appointing a proxy should not preclude a member from attending and voting in person at the above meeting and in such event, the instrument appointing a proxy shall be deemed to be revoked.*

---

## NOTICE OF ANNUAL GENERAL MEETING

---

- (4) *The register of members of the Company will be closed from Friday, 22 May 2026 to Thursday, 28 May 2026 (both days inclusive), during which period no transfer of shares in the Company will be registered. In order to qualify for entitlement to attend the meeting, all completed transfer forms, accompanied by the relevant share certificates, have to be lodged with the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration, not later than 4:30 p.m. on Thursday, 21 May 2026.*
- (5) *Shareholders should make their own decision as to whether they would attend the above meeting under bad weather conditions bearing in mind their own situation and if they should choose to do so, they are advised to exercise care and caution.*
- (6) *An explanatory statement containing further information concerning ordinary resolution No. 4 is set out in Appendix I to the circular of the Company dated 6 May 2026.*